Literature DB >> 25651103

Porous silicon microparticles for delivery of siRNA therapeutics.

Jianliang Shen1, Xiaoyan Wu2, Yeonju Lee3, Joy Wolfram4, Zhizhou Yang3, Zong-Wan Mao5, Mauro Ferrari6, Haifa Shen7.   

Abstract

Small interfering RNA (siRNA) can be used to suppress gene expression, thereby providing a new avenue for the treatment of various diseases. However, the successful implementation of siRNA therapy requires the use of delivery platforms that can overcome the major challenges of siRNA delivery, such as enzymatic degradation, low intracellular uptake and lysosomal entrapment. Here, a protocol for the preparation and use of a biocompatible and effective siRNA delivery system is presented. This platform consists of polyethylenimine (PEI) and arginine (Arg)-grafted porous silicon microparticles, which can be loaded with siRNA by performing a simple mixing step. The silicon particles are gradually degraded over time, thereby triggering the formation of Arg-PEI/siRNA nanoparticles. This delivery vehicle provides a means for protecting and internalizing siRNA, without causing cytotoxicity. The major steps of polycation functionalization, particle characterization, and siRNA loading are outlined in detail. In addition, the procedures for determining particle uptake, cytotoxicity, and transfection efficacy are also described.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25651103      PMCID: PMC4354534          DOI: 10.3791/52075

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  17 in total

1.  Degradation and biocompatibility of multistage nanovectors in physiological systems.

Authors:  Jonathan O Martinez; Michael Evangelopoulos; Ciro Chiappini; Xuewu Liu; Mauro Ferrari; Ennio Tasciotti
Journal:  J Biomed Mater Res A       Date:  2013-11-16       Impact factor: 4.396

Review 2.  Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity.

Authors:  A Christy Hunter
Journal:  Adv Drug Deliv Rev       Date:  2006-09-28       Impact factor: 15.470

3.  Dose-dependent movement of cationic molecules across the glomerular wall.

Authors:  P M Andrews; S B Bates
Journal:  Anat Rec       Date:  1985-07

4.  Size and shape effects in the biodistribution of intravascularly injected particles.

Authors:  P Decuzzi; B Godin; T Tanaka; S-Y Lee; C Chiappini; X Liu; M Ferrari
Journal:  J Control Release       Date:  2009-10-27       Impact factor: 9.776

Review 5.  siRNA delivery systems for cancer treatment.

Authors:  Yu-Kyoung Oh; Tae Gwan Park
Journal:  Adv Drug Deliv Rev       Date:  2009-05-05       Impact factor: 15.470

6.  Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells.

Authors:  Mingzhen Zhang; Rong Xu; Xiaojun Xia; Yong Yang; Jianhua Gu; Guoting Qin; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  Biomaterials       Date:  2013-10-05       Impact factor: 12.479

7.  Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity.

Authors:  Arkadi Zintchenko; Alexander Philipp; Ali Dehshahri; Ernst Wagner
Journal:  Bioconjug Chem       Date:  2008-06-14       Impact factor: 4.774

8.  High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.

Authors:  Jianliang Shen; Rong Xu; Junhua Mai; Han-Cheon Kim; Xiaojing Guo; Guoting Qin; Yong Yang; Joy Wolfram; Chaofeng Mu; Xiaojun Xia; Jianhua Gu; Xuewu Liu; Zong-Wan Mao; Mauro Ferrari; Haifa Shen
Journal:  ACS Nano       Date:  2013-10-18       Impact factor: 15.881

Review 9.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

Review 10.  Knocking down barriers: advances in siRNA delivery.

Authors:  Kathryn A Whitehead; Robert Langer; Daniel G Anderson
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

View more
  14 in total

1.  A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.

Authors:  Bronwyn Scott; Jianliang Shen; Sara Nizzero; Kathryn Boom; Stefano Persano; Yu Mi; Xuewu Liu; Yuliang Zhao; Elvin Blanco; Haifa Shen; Mauro Ferrari; Joy Wolfram
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

2.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

Review 3.  Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles.

Authors:  Sara Busatto; Anthony Pham; Annie Suh; Shane Shapiro; Joy Wolfram
Journal:  Biomed Microdevices       Date:  2019-04-15       Impact factor: 2.838

4.  Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.

Authors:  Carlotta Borsoi; Fransisca Leonard; Yeonju Lee; Mohamed Zaid; Dalia Elganainy; Jenolyn Francisca Alexander; Megumi Kai; Yan Ting Liu; Yaan Kang; Xuewu Liu; Eugene J Koay; Mauro Ferrari; Biana Godin; Kenji Yokoi
Journal:  Cancer Lett       Date:  2017-07-04       Impact factor: 8.679

5.  Enzyme-responsive multistage vector for drug delivery to tumor tissue.

Authors:  Yu Mi; Joy Wolfram; Chaofeng Mu; Xuewu Liu; Elvin Blanco; Haifa Shen; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2016-08-19       Impact factor: 7.658

Review 6.  Multistage vector (MSV) therapeutics.

Authors:  Joy Wolfram; Haifa Shen; Mauro Ferrari
Journal:  J Control Release       Date:  2015-08-08       Impact factor: 9.776

7.  Post-nano strategies for drug delivery: Multistage porous silicon microvectors.

Authors:  Alessandro Venuta; Joy Wolfram; Haifa Shen; Mauro Ferrari
Journal:  J Mater Chem B       Date:  2016-11-26       Impact factor: 6.331

Review 8.  Lipoprotein-based drug delivery.

Authors:  Sara Busatto; Sierra A Walker; Whisper Grayson; Anthony Pham; Ming Tian; Nicole Nesto; Jacqueline Barklund; Joy Wolfram
Journal:  Adv Drug Deliv Rev       Date:  2020-08-11       Impact factor: 15.470

9.  Hesperetin Liposomes for Cancer Therapy.

Authors:  Joy Wolfram; Bronwyn Scott; Kathryn Boom; Jianliang Shen; Carlotta Borsoi; Krishna Suri; Rossella Grande; Massimo Fresta; Christian Celia; Yuliang Zhao; Haifa Shen; Mauro Ferrari
Journal:  Curr Drug Deliv       Date:  2016       Impact factor: 2.565

10.  Extracellular vesicle therapeutics from plasma and adipose tissue.

Authors:  Dalila Iannotta; Man Yang; Christian Celia; Luisa Di Marzio; Joy Wolfram
Journal:  Nano Today       Date:  2021-04-27       Impact factor: 18.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.